Patrys Ltd Mel (PATZF) 0.0100 $PATZF
Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl8zck/colon_carcinoma) has announced the addition of the "Colon Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aposense Ltd. - Teva Pharmaceutical Industries Limited - Patrys Limited - Philogen S.p.A. - AIMM Therapeutics B.V. Drug Profiles - CEP-37250 - PAT-LM1 - ATT-11T - CIGB-247 - Antibody for Oncology - Small Molecules to Inhibit Tubulin for Oncology - Monoclonal Antibody for Colon Carcinoma - methoxynaphthylfenoterol - Vaccine for Lymphoma and Colon Carcinoma - Recombinant Protein to Activate IL-2 Receptor for Oncology - Adhesio-mAb - Anti-MFG-E8 Mab - F8IL-4 - Peptide for Colon Carcinoma - Antibody to Inhibit Rspo2 and Rspo3 for Oncology For more information visit http://www.researchandmarkets.com/research/sl..._carcinoma
Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report
M2 - Wed Feb 19, 2:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg3jt3/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections. - A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Staphylococcus Aureus Infections Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Staphylococcus Aureus Infections - Therapeutics Assessment Drug Profiles lysostaphin - Drug Profile WCK-771 - Drug Profile avarofloxacin hydrochloride - Drug Profile PF-06290510 - Drug Profile P-128 - Drug Profile GSK-2392106A - Drug Profile STEBVax - Drug Profile GSK-2392105A - Drug Profile GSK-2392103A - Drug Profile GSK-2392019A - Drug Profile NDV-3 Vaccine - Drug Profile SASPject PT1.2 - Drug Profile GSK-2392102A - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile MEDI-4893 - Drug Profile MORAb-048 - Drug Profile gallium citrate Ga 67 - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile NVC-727 - Drug Profile SEB-HIG - Drug Profile SEB-HuMab - Drug Profile Bactericidal Venom-Based Polypeptides - Drug Profile MGB-BP-3 - Drug Profile Second Generation Oxas - Drug Profile Novarifyn - Drug Profile AQP-182 - Drug Profile niacinamide - Drug Profile Vaccine For Staphylococcus - Drug Profile and many more..... Featured News & Press Releases Appendix List of Tables List of Figures Some of the Companies Mentioned AstraZeneca PLC GlaxoSmithKline plc Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Exploit Technologies Pte Ltd Imaxio Novartis AG Actelion Ltd Pfizer Inc. Wockhardt Limited NovaBay Pharmaceuticals, Inc. Patrys Limited Galapagos NV Microbio Co., Ltd. Morphotek, Inc. Bharat Biotech International Limited Novabiotics Ltd GlycoVaxyn AG Priaxon AG Aquapharm Biodiscovery Limited Aridis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/jg...hylococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Colon Carcinoma Therapeutics Pipeline Report 2014 - 5 Companies & 15 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl8zck/colon_carcinoma) has announced the addition of the "Colon Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aposense Ltd. - Teva Pharmaceutical Industries Limited - Patrys Limited - Philogen S.p.A. - AIMM Therapeutics B.V. Drug Profiles - CEP-37250 - PAT-LM1 - ATT-11T - CIGB-247 - Antibody for Oncology - Small Molecules to Inhibit Tubulin for Oncology - Monoclonal Antibody for Colon Carcinoma - methoxynaphthylfenoterol - Vaccine for Lymphoma and Colon Carcinoma - Recombinant Protein to Activate IL-2 Receptor for Oncology - Adhesio-mAb - Anti-MFG-E8 Mab - F8IL-4 - Peptide for Colon Carcinoma - Antibody to Inhibit Rspo2 and Rspo3 for Oncology For more information visit http://www.researchandmarkets.com/research/sl..._carcinoma
Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report
M2 - Wed Feb 19, 2:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/jg3jt3/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering. 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Scope - A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections. - A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Staphylococcus Aureus Infections Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Staphylococcus Aureus Infections - Therapeutics Assessment Drug Profiles lysostaphin - Drug Profile WCK-771 - Drug Profile avarofloxacin hydrochloride - Drug Profile PF-06290510 - Drug Profile P-128 - Drug Profile GSK-2392106A - Drug Profile STEBVax - Drug Profile GSK-2392105A - Drug Profile GSK-2392103A - Drug Profile GSK-2392019A - Drug Profile NDV-3 Vaccine - Drug Profile SASPject PT1.2 - Drug Profile GSK-2392102A - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile MEDI-4893 - Drug Profile MORAb-048 - Drug Profile gallium citrate Ga 67 - Drug Profile Staphylococcus Aureus Vaccine - Drug Profile NVC-727 - Drug Profile SEB-HIG - Drug Profile SEB-HuMab - Drug Profile Bactericidal Venom-Based Polypeptides - Drug Profile MGB-BP-3 - Drug Profile Second Generation Oxas - Drug Profile Novarifyn - Drug Profile AQP-182 - Drug Profile niacinamide - Drug Profile Vaccine For Staphylococcus - Drug Profile and many more..... Featured News & Press Releases Appendix List of Tables List of Figures Some of the Companies Mentioned AstraZeneca PLC GlaxoSmithKline plc Genentech, Inc. Daiichi Sankyo Company, Limited Merck & Co., Inc. Exploit Technologies Pte Ltd Imaxio Novartis AG Actelion Ltd Pfizer Inc. Wockhardt Limited NovaBay Pharmaceuticals, Inc. Patrys Limited Galapagos NV Microbio Co., Ltd. Morphotek, Inc. Bharat Biotech International Limited Novabiotics Ltd GlycoVaxyn AG Priaxon AG Aquapharm Biodiscovery Limited Aridis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/jg...hylococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
